MARINO, MARCO
 Distribuzione geografica
Continente #
NA - Nord America 241
AS - Asia 163
EU - Europa 157
SA - Sud America 29
AF - Africa 3
Totale 593
Nazione #
US - Stati Uniti d'America 239
SG - Singapore 84
IT - Italia 71
CN - Cina 36
IE - Irlanda 25
BR - Brasile 22
DE - Germania 21
SE - Svezia 13
VN - Vietnam 13
FR - Francia 7
ID - Indonesia 6
AR - Argentina 5
IN - India 5
GB - Regno Unito 4
UA - Ucraina 4
JP - Giappone 3
KR - Corea 3
AT - Austria 2
BD - Bangladesh 2
FI - Finlandia 2
IQ - Iraq 2
MX - Messico 2
NG - Nigeria 2
NL - Olanda 2
TR - Turchia 2
AM - Armenia 1
AZ - Azerbaigian 1
BE - Belgio 1
CH - Svizzera 1
CO - Colombia 1
EG - Egitto 1
ES - Italia 1
GR - Grecia 1
HK - Hong Kong 1
IL - Israele 1
KZ - Kazakistan 1
LT - Lituania 1
PK - Pakistan 1
PL - Polonia 1
TW - Taiwan 1
VE - Venezuela 1
Totale 593
Città #
Chandler 60
Singapore 46
Santa Clara 29
Dublin 25
Turin 23
Beijing 15
Ashburn 13
Nyköping 11
Jacksonville 9
Dong Ket 8
Torino 8
Munich 7
Boardman 6
Jakarta 6
Columbus 5
Los Angeles 5
Medford 5
Rome 5
Buffalo 4
Crescentino 4
Hamburg 4
Princeton 4
São Paulo 4
Ann Arbor 3
Bari 3
Duncan 3
Frankfurt am Main 3
Hefei 3
Milan 3
New York 3
Palermo 3
San Francisco 3
Seoul 3
Wilmington 3
Abuja 2
Clifton 2
Dearborn 2
Helsinki 2
Lauterbourg 2
Lucca 2
Mexico City 2
Mumbai 2
Nuremberg 2
Parma 2
Pune 2
Redondo Beach 2
Seattle 2
Zola Predosa 2
Armação dos Búzios 1
Astana 1
Athens 1
Baghdad 1
Baku 1
Bengaluru 1
Boston 1
Brussels 1
Buenos Aires 1
Bursa 1
Cairo 1
Cambuquira 1
Campina Grande 1
Caracas 1
El Carmen de Bolívar 1
Fairfield 1
Fazenda Rio Grande 1
Fortaleza 1
Franca 1
Guarulhos 1
Haifa 1
Hanoi 1
Ho Chi Minh City 1
Hong Kong 1
Houston 1
Iguape 1
Izmir 1
Jequié 1
Lahore 1
Lilburn 1
London 1
Maringá 1
Matinhos 1
Menlo Park 1
Mesquita 1
Monte Azul Paulista 1
Nanchang 1
Nanjing 1
Nashville 1
Newark 1
Ninh Bình 1
Olivos 1
Orem 1
Porto Alegre 1
Puerto Madryn 1
Redwood City 1
Resistencia 1
Richmond 1
Roubaix 1
Secaucus 1
Swansea 1
São Bernardo do Campo 1
Totale 419
Nome #
Pharmacological characterization of new NLRP3 inflammasome inhibitors. 117
Investigation into the Use of Encorafenib to Develop Potential PROTACs Directed against BRAFV600E Protein 111
Covalent NLRP3 inhibitors: design strategies, synthesis and pharmacological characterization 103
Targeting NLRP3 inflammasome: development of new covalent and non-covalent inhibitors of ATPase activity 100
NEW NON-COVALENT INHIBITORS OF NLRP3 INFLAMMASOME ATPASE ACTIVITY 100
Design and synthesis of encorafenib-based BRAF-V600E degraders 70
Totale 601
Categoria #
all - tutte 2.244
article - articoli 0
book - libri 0
conference - conferenze 1.663
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 3.907


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202124 0 0 0 0 0 0 0 0 7 0 2 15
2021/202246 0 1 0 0 1 4 1 1 4 4 15 15
2022/2023152 9 22 1 25 6 48 6 8 7 3 8 9
2023/202453 9 8 4 2 1 2 0 7 0 2 2 16
2024/2025184 6 0 16 17 33 20 8 10 29 4 15 26
2025/2026108 24 7 11 35 29 2 0 0 0 0 0 0
Totale 601